##plugins.themes.academic_pro.article.sidebar##
Main Article Content
Abstract
Konsumsi ethanol merupakan salah satu penyebab dyslipidemia sekunder dan telah menyebabkan
kematian penduduk dengan rata-rata usia 20-39 tahun, yang kurang lebih setara dengan 13,5% dari
total seluruh kematian menurut WHO 2022. Ditandai dengan ketidakteraturan lemak darah seperti
penurunan HDL, peningkatan LDL. Ethanol juga menyebabkan penurunan katalase sehingga ROS
dalam tubuh meningkat. VCO telah banyak diteliti terutama untuk antioksidan, antiinflamasi, dan
dapat meningkatkan kadar lemak baik. Penelitian ini berfokus pada terapi pencegahan dan bertujuan
untuk membandingkan profil HDL, LDL, dan katalase antara tikus kelompok kontrol dan kelompok
perlakuan setelah pemberian VCO. Design penelitian ini merupakan eksperimental “post-test only
control group design”, terdiri dari 30 tikus yang dibagi menjadi 3 kelompok: kelompok tanpa
perlakuan (K1), kelompok induksi ethanol 4,5g/Kg (20% v/v) (K2), kelompok perlakuan VCO
1ml/hari/270g BB (KP). Hasil Uji one-way ANOVA HDL didapatkan penurunan tidak signifikan
pada K1-K2 (p=0,187) dan peningkatan signifikan pada K2-KP (p=0,010), sedangkan Uji one-way
ANOVA LDL didapatkan peningkatan tidak signifikan (p=0,390) pada K1-K2 dan penurunan tidak
signifikan (p=0,168) pada K2-KP, yang menunjukkan bahwa induksi ethanol yang telah dilakukan
belum berhasil memengaruhi profil lipid HDL dan LDL darah. Tetapi, hasil Uji one-way ANOVA
katalase menunjukkan penurunan yang signifikan pada K1-K2 (p= 0,028), dan peningkatan
signifikan pada K2-KP (p=0,001), yang menunjukkan bahwa induksi ethanol berhasil memengaruhi
kadar katalase, dan VCO dapat meningkatkan kadar katalase darah.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
2. Malik DK, Sharma D, Gulia D, Chugh D, Dahiya K. Dyslipidemia in Alcoholic Liver Disease. Int J Adv Res. 2016;4(10):1090–4.
3. Lin CF, Chang YH, Chien SC, Lin YH, Yeh HY. Epidemiology of Dyslipidemia in the Asia Pacific Region. Int J Gerontol. 2018;12(1):2–6.
4. Purva A, Sharma K, Khan MS. A Review on Dyslipidemia: Types, Risk Factors and Management. Asian J Pharm Res Dev.
2020;8(2):96–8.
5. O’Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovascular health: the razor-sharp double- edged sword. J Am Coll Cardiol [Internet].
2007 Sep 11 [cited 2022 Jul 3];50(11):1009–
14. Available from:
https://pubmed.ncbi.nlm.nih.gov/17825708/
6. Le Daré B, Lagente V, Gicquel T. Ethanol and its metabolites: update on toxicity, benefits, and focus on immunomodulatory effects. Drug Metab Rev [Internet]. 2019;51(4):545–61. Available from: https://doi.org/10.1080/03602532.2019.167916
9
7. Akbar M, Egli M, Cho YE, Song BJ, Noronha A. Medications for alcohol use disorders: An overview. Pharmacol Ther. 2018;185:64–85.
8. (NIAAA) NI on AA and A. Harmful
Interactions: Mixing Alcohol. Read. 2014;1–9.
9. Yang C, Tang D. Reference-Dose Place
Conditioning with Ethanol in Mice: Empirical and Theoritical Analysis. Ref Place Cond with Ethanol Mice Empir Theor Anal [Internet].
2000;1(2):119–31. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PM C2883454/
10. Shariq B, Zulhabri O, Hamid K, Sundus B,
Mehwish H, Sakina R, et al. Evaluation of
Anti-Atherosclerotic Activity of Virgin Coconut Oil in Male Wistar Rats Against High Lipid and High Carbohydrate Diet Induced Atherosclerosis. Pharm Biosci J.
2015;(May):10–4.
11. Shirpoor A, Salami S, Khadem-Ansari MH,
Heshmatian B, Ilkhanizadeh B. Long-term ethanol consumption initiates atherosclerosis in rat aorta through inflammatory stress and endothelial dysfunction. Vascul Pharmacol.
2012 Sep 1;57(2–4):72–7.
12. Dayrit FM. Lauric acid is a medium-chain
fatty acid, coconut oil is a medium-chain triglyceride. Philipp J Sci. 2014;143(2):157–
66.
13. Chinwong S, Chinwong D, Mangklabruks A.
Daily Consumption of Virgin Coconut Oil Increases High-Density Lipoprotein Cholesterol Levels in Healthy Volunteers: A Randomized Crossover Trial. Evidence- based Complement Altern Med. 2017;2017.
14. Babu AS, Veluswamy SK, Arena R, Guazzi
M, Lavie CJ. Virgin coconut oil and its potential cardioprotective effects. Postgrad Med. 2014;126(7):76–83.
15. Arunima S, Rajamohan T. Influence of
virgin coconut oil-enriched diet on the transcriptional regulation of fatty acid synthesis and oxidation in rats-a comparative study. Br J Nutr. 2014;111(10):1782–90.
16. MKing. Peroxisome proliferator-activated receptors, ppars. 2022.
17. Wang Z, Yao T, Song Z. Chronic alcohol
consumption disrupted cholesterol
homeostasis in rats: Down-regulation of low- density lipoprotein receptor and
enhancement of cholesterol biosynthesis pathway in the liver. Alcohol Clin Exp Res.
2010;34(3):471–8.
18. Jaarin K, Norliana M, Kamisah Y,
Nursyafiza M, Qodriyah HMS. Potential role of virgin coconut oil in reducing cardiovascular risk factors: Original article. Exp Clin Cardiol. 2014;20(8):3399–410.
19. Ramanathan N, Tan E, Loh LJ, Soh BS, Yap WN. Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities. Nutr Metab. 2018;15(1):1–15.
20 Vysakh A, Ratheesh M, Rajmohanan TP, Pramod C, Premlal S, Girish Kumar B, et al. Polyphenolics isolated from virgin coconut oil inhibits adjuvant induced arthritis in rats through antioxidant and anti-inflammatory action. Int Immunopharmacol [Internet]. 2014;20(1):124–30. Available from: http://dx.doi.org/10.1016/j.intimp.2014.02.026
21. Kesuma Y. Antioksidan Alami dan Sintetik. 2015. 15–16 p.
22. Illam SP, Narayanankutty A, Raghavamenon AC. Polyphenols of virgin coconut oil prevent pro-oxidant mediated cell death. Toxicol Mech Methods [Internet]. 2017;27(6):442–50. Available from: http://dx.doi.org/10.1080/15376516.2017.1320458